PBYI — Puma Biotechnology Share News
0.000.00%
Last trade - 00:00- $581.24m
- $487.34m
- $228.37m
Brief: Puma Biotech Reports First Quarter Financial Results
Puma Biotechnology Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Puma Biotechnology Announces Publication Of Phase Ii Clinical Trial Of Alisertib In Jama Oncology
Puma Biotechnology Inc reports results for the quarter ended in December - Earnings Summary
Brief: Puma Biotechnology Reports Q4 And Full Year Financial Results
Puma Biotechnology Inc expected to post earnings of 5 cents a share - Earnings Preview
Brief: Puma Biotechnology Inc Says Effective Dec 13, Co, Wyeth, LLC Entered Into Settlement, License Agreement With Sandoz Inc
Brief: Puma Biotechnology Presents Updated Findings From The TBCRC-022 Trial At The 2022 San Antonio Breast Cancer Symposium
Puma Biotechnology Inc reports results for the quarter ended in September - Earnings Summary
Puma Biotechnology Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Puma Biotechnology Announces Exclusive License Agreement With Takeda For Development, Commercialization Of Alisertib
Brief: Puma Biotechnology Reports Second Quarter 2022 Financial Results
Puma Biotech dips on stock offering by investor
Brief: Puma Biotechnology Inc Files For An Offering Of Up To 1.79 Mln Shares By Selling Stockholder
Brief: Puma Biotechnology Presents Outcomes From The Metastatic Breast Cancer Cohort
Brief: Puma Biotechnology Presents Final Results From Biliary Tract Cohort Of Phase 2 Summit 'Basket' Trial Of Neratinib
Brief: Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The 2022 Asco Annual Meeting
Brief: Puma Biotechnology Reports First Quarter 2022 Financial Results
Puma Biotechnology Inc reports results for the quarter ended in March - Earnings Summary